PAR-25-024-Full-Announcement.html

The document is a Funding Opportunity Announcement (FOA) for the "Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)" grant program. The purpose of this FOA is to promote the discovery and early evaluation of candidate biomarkers and biomarker signatures that can facilitate the clinical development of neurotherapeutics and their use in clinical practice. The funding is provided by the Department of Health and Human Services' National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA). Eligible applicant types include city/township governments, public housing authorities, for-profit organizations, state governments, higher education institutions, county governments, tribal organizations, independent school districts, non-501(c)(3) nonprofits, tribal governments, small businesses, and special district governments. The goal is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.